DOJ Filing Reawakens Fraud-On-The-FDA Theory Of Liability
On June 3, the U.S. Department of Justice Civil Division's Washington, D.C., office filed a statement of interest[1] in a relator's action, arguing that "[c]onduct giving rise to a regulatory violation...To view the full article, register now.
Already a subscriber? Click here to view full article